Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03595501 · ClinicalTrials.gov registry record
Analytical and Clinical Performance Testing Plan
A clinical trial of Hematology and Hematologic Test, sponsored by Sight Diagnostics.
- Completed
- Registry status
- 679
- Enrollment target
- 1
- Study location
NCT03595501 is a study of Hematology and Hematologic Test that has completed, run by Sight Diagnostics. The registered enrollment target is 679 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03595501, a study of Hematology and Hematologic Test, has completed, sponsored by Sight Diagnostics.
- COMPLETED
- Registry status
- 679 participants
- Enrollment target
- 1
- Study location
Study Summary
Clinical and analytical tests will be performed based on risk assessment and system specifications to verify that the performance of the investigational device is in accordance with its specifications.
Conditions Studied
Interventions
- DEVICE Hematology Analyzer - OLO
- DEVICE Hematology Analyzer - Predicate
Study Locations (1)
New York
- Columbia University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 679 participants |
| Start Date | 2018-06-20 |
| Est. Completion | 2019-08-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03595501
The ClinicalTrials.gov registry entry for NCT03595501 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 679 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sight Diagnostics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hematology appearing as the primary indexed condition, and to 2 interventions - of which Hematology Analyzer - OLO is the first listed.
NCT03595501 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03595501 about?
NCT03595501 is a clinical study titled "Analytical and Clinical Performance Testing Plan". Clinical and analytical tests will be performed based on risk assessment and system specifications to verify that the performance of the investigational device is in accordance with its specifications.
What is the current status of trial NCT03595501?
This trial is currently completed. The enrollment target is 679 participants. The study started on 2018-06-20. Estimated completion is 2019-08-25.
What conditions does trial NCT03595501 study?
This clinical trial studies the following conditions: Hematology, Hematologic Test.
What interventions are being tested in trial NCT03595501?
The interventions under investigation include: Hematology Analyzer - OLO (DEVICE), Hematology Analyzer - Predicate (DEVICE).
Who is sponsoring clinical trial NCT03595501?
This trial is sponsored by Sight Diagnostics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03595501 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematology
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.